NICE backs Palforzia for the treatment of peanut allergy in children
USA-based biotech Aimmune Therapeutics, which is now fully owned by Swiss foods giant Nestle (NESN: VX), today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended Palforzia [defatted powder of Arachis hypogaea L, semen (peanuts)] or use within the National Health Service (NHS) for the treatment of peanut allergy in patients aged four to 17.
Highlights:
- The recommendation was based on resultsfrom the PALISADE, ARTEMIS and the ARC004/PALISADE follow-on clinical studies;
- The studies met primary, secondary and safety endpoints for patients aged four to 17 and demonstrated that patients treated with Palforzia experienced desensitization to peanut with an anticipated and manageable safety profile;
- Palforzia is indicated in patients aged four to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older;
- Palforzia is the first peanut allergy treatment licensed and available to patients living in England; and
- Peanut allergy affects between 0.5%-2.5% of children in the UK
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze